Last reviewed · How we verify
NCT02652377
EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients
Phase 1 trial testing EDP-494 in Hepatitis C in 100 participants. Completed in 27 December 2016.
27 December 2016
Quick facts
| Lead sponsor | Enanta Pharmaceuticals, Inc |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 10 January 2016 |
| Primary completion | 27 December 2016 |
| Estimated completion | 27 December 2016 |
| Sites | 1 location across New Zealand |
Drugs / interventions tested
- EDP-494 — full drug profile →
- Placebo
Conditions studied
- Hepatitis C — all drugs for Hepatitis C →
Sponsor
Enanta Pharmaceuticals, Inc — full company profile →
Who can join
Adults 18 to 70, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized, double-blind study will assess the safety, pharmacokinetics and efficacy of a single and multiple dose(s) of orally QD administered EDP-494 in healthy volunteers (HV) and in treatment-naive subjects with GT1/3 chronic hepatitis C (CHC) infection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections.
Meshram RJ, Kathwate GH, Gacche RN. · · 2022 · cited 9× · PMID 35089390 · DOI 10.1007/s00705-022-05375-0
Verify or expand the search:
- PubMed search for NCT02652377
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatitis C
Currently open trials in the same condition.
- NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
- NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
- NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
- NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
- NCT05208697 — Tele-Harm Reduction · NA · active not recruiting
Other Enanta Pharmaceuticals, Inc trials
Trials by the same sponsor.
- NCT06917508 — A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participa · Phase 1 · completed
- NCT06847464 — A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the P · Phase 1 · completed
- NCT06601192 — A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults · Phase 1 · completed
- NCT06170242 — A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus · Phase 2 · completed
- NCT05568706 — A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02652377 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Enanta Pharmaceuticals, Inc
- Last refreshed: 23 January 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02652377.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing